exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087581 RNA Name: hsa-let-7a-5p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 94175962 End Site(bp): 94175983 External Links: hsa-let-7a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand HMGA1 chr6 34236873 34246231 + PDPR chr16 70113626 70162537 + ERO1A chr14 52639915 52695900 - UBE2G2 chr21 44768580 44801826 - CD82 chr11 44564427 44620358 + YOD1 chr1 207043849 207052980 - HMGA2 chr12 65824131 65966295 + MYL12A chr18 3247481 3256236 + CTPS2 chrX 16587999 16712936 - MARCKSL1 chr1 32333839 32336233 - AGRN chr1 1020120 1056118 + STK4 chr20 44966479 45080021 + BRD4 chr19 15235519 15332545 - C1orf43 chr1 154206696 154220637 - PLD3 chr19 40348456 40380439 + BACH1 chr21 29194071 29630751 + PPARA chr22 46150521 46243756 + WDR83OS chr19 12668073 12669415 - BCAM chr19 44809071 44821421 + IGF2BP1 chr17 48997385 49056145 + SNRPC chr6 34757505 34773857 + COIL chr17 56938199 56961050 - RANBP2 chr2 108719482 108785809 + ZNF576 chr19 43596392 43601157 + BLOC1S6 chr15 45587214 45615945 + ARHGAP28 chr18 6729718 6915716 + TRIM65 chr17 75880335 75896951 - NHLRC3 chr13 39038306 39050109 + TAF4 chr20 61953469 62065810 - IGDCC3 chr15 65327127 65378002 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000247 chr10 74474868 74475660 + hsa_circ_0000987 chr2 30748452 30756180 + hsa_circ_0000246 chr10 74468040 74475660 + hsa_circ_0000018 chr1 15860731 15863309 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0000799 chr17 65941524 65972074 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC006064.5 chr12 6510275 6510522 + AC074117.1 chr2 27356246 27367622 + AC109460.3 chr16 28974804 28990775 + AC124045.1 chr3 44667412 44669364 + AL359924.1 chr1 237862175 237928321 + AP000766.1 chr11 107312132 107316271 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - KCNQ1OT1 chr11 2608328 2699994 - LINC00265 chr7 39733430 39793092 + LINC02381 chr12 54126082 54147485 + MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - SNHG16 chr17 76557764 76565348 + SNHG4 chr5 139274102 139284899 + TMPO-AS1 chr12 98512973 98516422 - XIST chrX 73820649 73852723 - ZNF436-AS1 chr1 23368997 23371839 + AD000090.1 chr19 35557956 35581954 + LINC01744 chr1 232727251 232751299 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.